| Description | Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer. |
| Synonyms | IBI308, Sintilimab (anti-PD-1) |
| molecular weight | N/A |
| CAS | 2072873-06-2 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
| References | 1. Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79(3):341-346. 2. Lu S, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023 Jul;11(7):624-636. |